Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18737015 | 0.88 | CHRM4 (0.44) | KDM1AGNAI3GNAO1GNAI1CHRM4 | |
| SCHEMBL14330956 | 0.87 | PKM (0.34) | KDM1AKDM4EALDH1A1 | |
| SCHEMBL18737047 | 0.85 | HRH3 (0.46) | MAPK1CHRM4CHRM5CHRM3KDM4E | |
| SCHEMBL20076264 | 0.84 | ALDH1A1 (0.39) | MAPK1RAB9AGNAI3GNAO1GNAI1 | |
| SCHEMBL18649626 | 0.83 | HRH3 (0.50) | MAPK1CHRM4CHRM5CHRM3KDM4E | |
| SCHEMBL15183482 | 0.83 | KDM1A (0.38) | KDM1AMAPK1RAB9AGNAI3GNAO1 | |
| SCHEMBL19861401 | 0.82 | PAOX (0.43) | GNAI3GNAO1GNAI1CHRM4CHRM5 | |
| SCHEMBL19861182 | 0.82 | CXCR4 (0.47) | KDM1AGNAI3GNAO1GNAI1CHRM4 | |
| SCHEMBL19861431 | 0.81 | ALDH1A1 (0.37) | GNAI3GNAO1GNAI1CHRM4CHRM5 | |
| SCHEMBL18410958 | 0.80 | SMN1; SMN2 (0.48) | MAPK1KDM4EALDH1A1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | KDM1A 3589/4885MAPK1 909/4885RAB9A 4712/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | KDM1A 3567/4885MAPK1 1050/4885RAB9A 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.